



HAL
open science

Multiple sclerosis: effect of beta interferon treatment on survival

Elaine Kingwell, Emmanuelle Leray, Feng Zhu, John Petkau, Gilles Edan,
Joel Oger, Helen Tremlett

► **To cite this version:**

Elaine Kingwell, Emmanuelle Leray, Feng Zhu, John Petkau, Gilles Edan, et al.. Multiple sclerosis: effect of beta interferon treatment on survival. *Brain - A Journal of Neurology* , 2019, 142 (5), pp.1324-1333. 10.1093/brain/awz055 . hal-02088095

HAL Id: hal-02088095

<https://univ-rennes.hal.science/hal-02088095>

Submitted on 5 Sep 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Multiple sclerosis: Effect of beta interferon treatment on survival

Running Title: Interferon and multiple sclerosis survival

Elaine Kingwell, PhD,¹ Emmanuelle Leray, PhD,²
Feng Zhu, MSc,¹ John Petkau, PhD,³ Gilles Edan, MD,⁴
Joel Oger, MD,¹ Helen Tremlett, PhD.¹

¹Faculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.

²EA 7449 REPERES, Ecole des Hautes Etudes en Santé Publique (EHESP), Rennes, Rennes Cedex, France

³Department of Statistics, University of British Columbia, Vancouver, BC, Canada.

⁴Centre Hospitalier Universitaire (CHU) de Rennes, Rennes, Rennes Cedex, France

Corresponding author:

Dr Elaine Kingwell

Faculty of Medicine (Neurology)

UBC Hospital, room S178

2211 Wesbrook Mall

Vancouver, BC, V6T 2B5

Canada

Tel: 604 822 7617

E-mail: elainejk@mail.ubc.ca

Manuscript Word Count: 4,029

Tables/figures: 4

ABSTRACT

Worldwide, the beta interferons remain the most commonly prescribed disease-modifying drugs for multiple sclerosis. However, it is unclear if they alter survival. We investigated the association between beta interferon and mortality in the ‘real-world’ setting. This was a multi-centre population-based observational study of patients with relapsing-onset multiple sclerosis who were initially registered at a clinic in British Columbia, Canada (1980-2004) or Rennes, France (1976-2013). Data on this cohort were accessed from the clinical multiple sclerosis databases and from individually linked health administrative data; all data were collected prospectively. Participants were followed from the later of their first multiple sclerosis clinic visit, 18th birthday or 1st January 1996; until death, emigration or 31st December 2013. Only those who were naïve to disease-modifying therapy and immunosuppressant treatment of multiple sclerosis at the start of their follow-up were included in the analysis. A nested case-control approach was used. Up to 20 controls, matched to cases (deaths) by country, sex, age+/- five years, year and disability level at study entry, were randomly selected from the cohort by incidence density sampling. The associations between all-cause mortality and at least six months beta interferon exposure, and also cumulative exposure (‘low’, six months to three years; and ‘high’, more than three years), were estimated by conditional logistic regression adjusting for treatment with other disease-modifying therapies and age in years. Further analyses included separate analyses by sex and country, additional adjustment for comorbidity burden in the Canadian cohort, and estimation of the association between beta interferon and multiple sclerosis-related death in both countries.

Among 5,989 participants (75% women) with a mean age of 42 [SD 11] years at study entry, there were 742 deaths (70% women) and the mean age at death was 61 [SD 13] years. Of these cases, 649 were matched to between one and 20 controls. Results of the conditional logistic regression analyses are expressed as adjusted odds ratios with 95% confidence intervals. The odds of beta interferon exposure were 32% lower among cases than controls (0.68; 0.53-0.89). Increased survival was associated with more than three years beta interferon exposure (0.44; 0.30-0.66), but not between six months and three years exposure (1.00; 0.73-1.38). Findings were similar within sex and country, and for multiple sclerosis-related death. Beta interferon treatment was associated with a lower mortality risk among people with relapsing-onset multiple sclerosis. Findings were consistent between two geographically distinct regions in North America and Europe.

Keywords: Mortality, survival; beta interferon; multiple sclerosis; nested case-control study

Abbreviations: CI Confidence interval; OR Odds ratio; SD Standard deviation

INTRODUCTION

Multiple sclerosis is a devastating chronic disease of the central nervous system that typically first affects young adults. Multiple sclerosis confers a survival disadvantage in comparison to the general population, with six to 14 fewer years lived (Bronnum-Hansen *et al.*, 2004; Kingwell *et al.*, 2012; Scalfari *et al.*, 2013; Rodriguez-Antiguedad Zarranz *et al.*, 2014; Leray *et al.*, 2015; Marrie *et al.*, 2015). Among people with multiple sclerosis, the proportion of deaths directly attributed to this condition has ranged from 50% to more than 75% (Sadovnick *et al.*, 1991; Midgard *et al.*, 1995; Koch-Henriksen *et al.*, 1998; Leray *et al.*, 2007; Rodriguez-Antiguedad Zarranz *et al.*, 2014; Leray *et al.*, 2015).

The first disease-modifying drugs, the beta interferons, were approved to treat relapsing-onset multiple sclerosis in the 1990s. Although newer therapies are now available, including orally active and infused medications, the beta interferons remain among the most commonly prescribed for multiple sclerosis worldwide (Multiple Sclerosis International Federation; Westad *et al.*, 2017). However, while they have shown modest efficacy in short-term clinical trials including reductions in relapse rates, relapse severity, and MRI abnormalities (IFNB Multiple Sclerosis Study Group, 1993; Johnson *et al.*, 1995; Jacobs *et al.*, 1996; PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, 1998) their effects on disability progression, or over the long-term and in clinical practice are less certain (Tramacere *et al.*, 2015; Signori *et al.*, 2016).

Preliminary observations from a small group of 366 individuals who were enrolled in one of the original beta interferon-1b clinical trials suggested that this drug might increase survival and reduce the risk of multiple sclerosis-related death (Goodin *et al.*, 2012a; Goodin *et al.*, 2012b). However, concerns were raised over the study design, including *post hoc* analyses in a small

group of clinical trial participants; it remains possible that the observed survival advantage was due to chance alone (Goodin and Reder, 2012; Gronseth and Ashman, 2012). Long-term randomized clinical trials that are specifically designed to assess the survival impact of disease-modifying therapies are neither feasible nor ethical. We utilized the nested case-control approach with a large population-based combined cohort of relapsing-onset multiple sclerosis patients from British Columbia, Canada and Rennes, France to examine the association of the beta interferons with all-cause, and multiple sclerosis-related, mortality in the real-world clinical setting.

MATERIALS AND METHODS

Data and cohort selection

We used prospectively collected linked data from population-based multiple sclerosis clinical and health administrative databases. The cohort comprised adults with relapsing-onset multiple sclerosis, initially registered at one of the four multiple sclerosis clinics in British Columbia between 1980 and 2004, or the Rennes multiple sclerosis clinic between 1976 and 2013. These individuals were inked to their health administrative data via unique personal health number (Canada), or name, sex, birthdate and birthplace (France). This enabled access to provincial (Canada) and national (France) death dates, and all causes listed on the death certificate.

Additional linkage, for Canada only, provided outpatient and community dispensations of disease-modifying therapy; hospital and physician derived diagnoses recorded via the International Classification of Diseases system to calculate the Charlson Comorbidity Index (Deyo *et al.*, 1992); registration dates in the compulsory provincial healthcare plan (to confirm residency in British Columbia; and quintiles of estimated socioeconomic status based on neighbourhood income. See Supplementary Methods 1 and Supplementary Table 1 for details.

Only persons with relapsing-onset multiple sclerosis (i.e. relapsing remitting or secondary progressive multiple sclerosis at study entry) who were naïve to any disease-modifying therapy or immunosuppressant at study entry were included. For the main analyses, an Expanded Disability Status Scale score within three years of study entry was required for inclusion. The study entry was the most recent of 1st January 1996, the first clinic visit, or the 18th birthday. The first full calendar year of beta interferon availability in both jurisdictions was 1996 (prior use was limited to clinical trials). Follow-up continued until the earlier of death, 31st December 2013 or, for the Canadian cohort only, emigration from the province of British Columbia. Such

censoring at emigration from British Columbia was necessary because death outcomes and treatment exposure were only captured for residents of the province. Treatment status after the last clinic visit was unknown for a subset of the French cohort; follow-up for these individuals was censored at their last clinic visit. However, all deaths registered anywhere in France were captured, and while emigration from France was not captured this was considered negligible.

Outcome and Exposure Measures

The primary outcome was death due to any cause; all persons who died during follow-up were considered cases. The secondary outcome was multiple sclerosis-related death, identified using the underlying or contributing causes on the death certificate by a study-specific algorithm formulated *a priori* (Figure 1). The algorithm was developed by reference to the existing literature on increased mortality risk due to specific causes among people with multiple sclerosis (Sadovnick *et al.*, 1991; Koch-Henriksen *et al.*, 1998; Bronnum-Hansen *et al.*, 2004; Grytten Torkildsen *et al.*, 2008; Smestad *et al.*, 2009; Sumelahti *et al.*, 2010; Goodin *et al.*, 2014), and by consensus of the study team which included two experienced multiple sclerosis specialist neurologists (GE and JO). For this analysis, multiple sclerosis-related deaths were cases and all other deaths in the cohort during follow up were censored on the date of death.

All beta interferons were considered as one group; ‘exposed’ was defined as six or more months of cumulative exposure between study entry and death, or between study entry and the analogous date for controls. Lower (six months to three years), or higher (more than three years) cumulative exposure to beta interferon was considered in secondary analysis to explore potential dose-response relationships; exposure duration categories were determined *a priori* based on the distribution of beta interferon exposure in the cases and controls combined. The effects of ‘early’ or ‘late’ beta interferon initiation were also examined by (i) time since multiple sclerosis

symptom onset (less than five and five or more years); and (ii) age (under 40 years and 40 years or older). Exposure to the second most commonly used disease-modifying therapy during this study period, glatiramer acetate (for at least six months) was considered as a covariate. The six month minimum exposure for beta interferon and glatiramer acetate was decided upon with reference to the minimum length of time that these agents might be expected to yield a clinical response (Karussis *et al.*, 2006). All other disease-modifying therapies that were available or approved during the study period (immunosuppressants such as azathioprine or mitoxantrone, as well as natalizumab and fingolimod) were combined into one variable and categorized as ‘any’ (at least one day) or ‘no’ exposure. The one day minimum exposure for the ‘other disease-modifying therapy’ variable reflects both its heterogeneous nature and the assumption that exposure to any duration of these therapies could serve as a marker for more severe disease. The sample size required to address the primary and secondary questions of the association between beta interferon and all-cause mortality, and MS-related mortality, was estimated *a priori*, assuming a two-tailed test with a 5% probability of type I error and at least 80% power. We anticipated sufficient power to assess the effects of beta interferon exposure on all-cause death, and MS-related death. Given low exposure rates for the non-beta interferon therapies (glatiramer acetate and ‘other’ disease modifying therapies) in this cohort, we did not have sufficient power to query their effects on survival; these exposures were measured and included in the analyses to adjust for confounding.

Study Design

A nested case-control approach was used with incidence density sampling. Up to 20 controls were randomly selected for each case, matched at study entry by sex, country, age (+/- five years), calendar year, and Expanded Disability Status Scale score (within three years of study

entry and categorized as scores of ≤ 3.0 ; 3.5-5.0; 5.5-6.5; >6.5). Hence, controls were alive at the time of the case's death, cases and controls were matched for follow-up duration, and eligible controls could be selected for more than one case or could become cases later during follow-up. If only 20 or fewer controls were available all available matched controls were used; all cases with at least one control were included in the analysis. The odds ratio (OR) estimated with this approach will be very similar to the hazard ratio that would be obtained using Cox regression modeling (when the parametric assumptions of the Cox model are met) of the whole cohort with time dependent disease-modifying therapy exposures (Essebag *et al.*, 2005). However, the nested case-control approach provides tighter control of the important confounding variables through matching. The cases are directly compared only to persons in the cohort who are still alive at the time of the death in the case and who are similar to them in terms of age; sex; disability level; and time period and duration of follow-up. As with the time dependent Cox model, the nested case-control approach accounts for the time dependence of exposure, and varying levels of exposure over time.

Statistical Analyses

The ORs and corresponding 95% CIs were estimated using conditional logistic regression models adjusted for a more precise measure of age (in years and months) at study entry, exposure to glatiramer acetate, and exposure to other disease-modifying therapies. Disease duration (years between multiple sclerosis onset and study entry), and in Canada only, the quintile of socioeconomic status at study entry and the Charlson Comorbidity Index measured over the year before study entry, were included in multivariable models only if associated with case-control status in the univariate model ($p \leq 0.1$). ORs were estimated for the combined cohort, and separately by country and sex.

Complementary analyses facilitated inclusion of additional data and tested assumptions by: allowing earlier study entry (1st January 1986); imputing Expanded Disability Status Scale scores for those without a score at study entry; imputing beta interferon status after the last clinic visit if subsequent treatment was unknown (France only); and changing criteria for exposure to beta interferon or glatiramer acetate to at least one day ('intention to treat'). More details are provided in Supplementary Methods 2.

The analyses were performed using R (version 3.4.2). The study was approved by the relevant ethics boards and data stewards (see acknowledgements).

Data Availability

The individual clinical data and linked administrative health and vital statistics data that support these findings are protected by strict privacy and data sharing agreements and cannot be distributed openly.

RESULTS

The combined Canadian and French cohort included 5,989 persons with relapsing-onset multiple sclerosis who were naïve to disease-modifying therapies at study entry; 75% were women and the mean age was 42 (SD 11) years. During an average of 11, and up to 18, years of follow-up 32% of persons in the cohort were exposed to beta interferon for at least six months, 12% to glatiramer acetate for at least six months, and 13% to another disease-modifying therapy for at least one day.

There were 742 deaths due to any cause (mean age at death was 61 years [SD 13]). Of these, 649 were successfully matched with up to 20 controls; the number of controls per case is shown in Supplementary Table 2. At study entry, cases were slightly older than controls, although by less than half a year (50.7 versus 50.3; $p=0.002$), and comparable by sex, Expanded Disability Status Scale score and country (Table 1). Comorbidity was associated with case-control status ($p=0.02$) in the Canadian cohort whereas multiple sclerosis disease duration and socioeconomic status were not ($p\geq 0.20$).

After adjustment for age and other disease-modifying therapy exposure, persons with relapsing-onset multiple sclerosis who died had lower odds of beta interferon exposure compared to persons with relapsing-onset multiple sclerosis who survived (OR:0.68; 95% CI:0.53-0.89); this can be interpreted as a 32% lower mortality risk for exposed compared to unexposed individuals. Increased survival was associated with a higher cumulative beta interferon exposure (more than three years; OR:0.44; 95% CI:0.30-0.66) but not with a lower exposure (between six months and three years; OR:1.00; 95% CI:0.73-1.38) (Table 2).

Stratified analyses by country (Table 2) and sex (Table 3), resulted in qualitatively similar findings, although CIs were wider in these subgroups. The adjusted ORs for Canada and France were essentially identical but for the smaller French cohort, with 80 matched cases, the CI included one (Table 2). While findings did not differ significantly between the sexes (the CIs overlapped), statistical significance was not reached for women except with higher cumulative beta interferon exposure. Further, the effect size was greater among men than among women (Table 3).

Since the analysis included people who died before the end of follow-up (cases) and their matched controls of comparable age, sex and disability level, both the average age (50 years) and the average disease duration (17 years) at study entry were greater than the average age and disease duration of the source cohort (i.e. those who were older or had a longer disease duration at study entry were less likely to survive to study end). The older age and more advanced disease duration at study start means that few had the opportunity to start treatment ‘early’ (at less than five years disease duration or under age 40); consequently, the proportion of cases and controls who initiated beta interferon early was less than 5% (Table 1). Our assessment of the effects of delayed initiation, whether measured by time since disease onset or age, resulted in findings consistent with the main analyses, with no evidence that late initiation was disadvantageous (the CIs for early and late initiation overlapped, and for early initiation they included one; Tables 2 and 3).

Among the 742 deaths, 489 (66%) were multiple sclerosis-related with a mean age at death of 59 years (SD 13); of these 433 were matched with up to 20 controls. As with all-cause deaths, the odds of beta interferon exposure were lower among multiple sclerosis-related death cases compared to their matched controls (OR:0.71; 95% CI:0.51-0.98). When analysed by cumulative

exposure or separately by sex, findings for multiple sclerosis-related death were similar to the all-cause death analysis (lower exposure: OR:1.15; 95% CI:0.78-1.68; higher exposure: OR:0.38; 95% CI:0.23-0.63; women OR:0.84; 95% CI:0.58-1.21; men OR:0.38; 95% CI:0.18-0.80).

An earlier study entry date (1st January 1986), imputation of missing Expanded Disability Status Scale scores, and imputation of treatment status for those with unknown beta interferon exposure after their last clinic visit allowed inclusion of more cases (up to 956) and a longer follow-up of up to 28 years. All findings from these complementary analyses, including the ‘intention to treat’ approach, were consistent with the main analyses although the estimated effect was greater with imputation of beta interferon exposure (see Supplementary Methods 2 and Supplementary Tables 3, 4, 5 and 6).

DISCUSSION

We observed a survival advantage associated with beta interferon exposure among persons with relapsing-onset multiple sclerosis; those who were exposed to beta interferon had a 32% lower mortality risk when compared to those who were not exposed. These findings were consistent between two geographically distinct multiple sclerosis cohorts, for men and women, and when only multiple sclerosis-related deaths were considered. Further, we found evidence of a cumulative dose response, with an increased survival associated with a longer (more than three years) but not with shorter (between six months and three years) cumulative exposure to beta interferon.

There are few published studies with which to compare our findings. Observations from a cohort of 366 relapsing-remitting multiple sclerosis participants in a beta interferon clinical trial, of which 81 died, suggested a survival advantage among those randomized to beta interferon compared to placebo 21 years previously (Goodin *et al.*, 2012*b*). However, there were no available data on the baseline distribution of risk factors for shorter survival, such as smoking, lipid status or comorbidity, and the analyses of the survival outcomes were *post-hoc* (Goodin and Reder, 2012; Gronseth and Ashman, 2012). A Taiwanese population-based study which included 88 deaths among 1,149 multiple sclerosis patients reported an apparent survival advantage for people who were treated with beta interferon or glatiramer acetate (Tsai and Lee, 2013) but, due to the inclusion of ‘immortal time’ (Suissa, 2008) in the study design, the findings would be expected to be biased in favour of treatment, rendering the findings indeterminate.

Interestingly, we found no evidence to suggest that later initiation of beta interferon (after 40 or five years of disease duration) was less advantageous than early initiation. While results from

some clinical trials have suggested a disadvantage with later (relative to earlier) Beta interferon initiation for other outcomes, including changes on magnetic resonance imaging, disability progression and transition from clinically isolated syndrome to definite multiple sclerosis (Bates, 2011; Freedman, 2011), these observations are from highly select groups of patients, typically excluding older adults such as those over 50 or 55 years, or those with longer disease duration (IFNB Multiple Sclerosis Study Group, 1993; Jacobs *et al.*, 1996; European Study Group on Interferon B-1b in Secondary Progressive MS, 1998; The OWIMS Study Group, 1999; Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS Study Group, 2001). In addition, findings from extension studies can potentially be affected by ‘informative censoring’ if those who do not do well are more likely to drop out and be lost to follow-up (Sormani and Bruzzi, 2015). Our results suggest that delayed treatment with beta interferon *can* provide benefit, although we had limited power to assess the effects of early initiation due to a low number of ‘early initiators’. This limitation is not surprising given that it is less than two and half decades since the beta-interferons first became available, and multiple sclerosis is not shortly fatal; recent studies have shown people with multiple sclerosis, on average, survive into their eighth decade of life (Kingwell *et al.*, 2012; Scalfari *et al.*, 2013; Leray *et al.*, 2015; Lunde *et al.*, 2017).

Previously, we found no significant associations between disability progression, as measured by Expanded Disability Status Scale milestones, and beta interferon exposure, although evidence of such an association has been inconsistent between studies (Tramacere *et al.*, 2015; Signori *et al.*, 2016). It is feasible that disability progression and survival are influenced by different factors and that an effect of beta interferon on survival is independent of any relationship with disability progression. Dissociation between outcomes in multiple sclerosis is not uncommon, notably for

relapses and Expanded Disability Status Scale score (Confavreux *et al.*, 2000; Tremlett *et al.*, 2009). Further, death is unarguably a more definitive representation of survival, and less susceptible to measurement error than the Expanded Disability Status Scale is of disability. One plausible mechanism through which the beta interferons might influence mortality is by a reduction in the risk of viral infections (Goodbourn *et al.*, 2000; Dhib-Jalbut and Marks, 2010). This study did not have sufficient power to assess death due to specific causes, such as infections; a larger cohort or longer follow-up would be required to gather sufficient cases by specific cause of death. Previous observations though have suggested a protective effect for hospitalizations for pneumonia/respiratory infection (Evans *et al.*, 2014) and, with at least two years cumulative exposure to beta interferon, for bronchitis or upper respiratory infections (de Jong *et al.*, 2017).

We were able to assess the association between beta interferon and multiple sclerosis-related deaths, as defined by the causes listed on the death certificate. The majority (66%) of deaths were considered multiple sclerosis-related; this falls within the range reported from other multiple sclerosis cohorts (Koch-Henriksen *et al.*, 1998; Bronnum-Hansen *et al.*, 2004; Leray *et al.*, 2007; Goodin *et al.*, 2012a; Rodriguez-Antiguedad Zarranz *et al.*, 2014), although some variation is to be expected due to different criteria for defining multiple sclerosis-related death and different ages and duration of follow-up. Similar to deaths due to any cause, we found a survival advantage for beta interferon exposure, with a 29% lower risk of multiple sclerosis-related death among treated, compared to untreated, persons with relapsing-onset multiple sclerosis.

The strengths of our study include up to 28 years follow-up of an international cohort with nearly 6,000 relapsing-onset multiple sclerosis patients (more than 7000 in complementary analyses)

from two distinct regions in North America and Europe, all of whom were diagnosed by specialist multiple sclerosis-neurologists, and a sizable number of death outcomes (649, rising to 956 in the complementary analyses). Access to population-based prospectively collected data ensured reliable and unbiased identification and coding of deaths, disease-modifying therapy exposure and, for the Canadian cohort, comorbidity information and estimates of socioeconomic status. The nested case-control approach with incidence density sampling provided an efficient study design with strict control of age, sex, year and disability level through matching, thus ensuring that controls were similar to cases and had the same duration of follow-up with equal opportunity for exposure to disease-modifying therapies during the same calendar time period. This approach has been shown to yield virtually identical findings to Cox regression modeling using the full cohort (Essebag *et al.*, 2005).

We were able to consider comorbidity and disability in our analyses; both were independent predictors of survival in our cohort and have previously been identified as important predictors of mortality in multiple sclerosis (Leray *et al.*, 2007; Marrie *et al.*, 2015; Salter *et al.*, 2016).

While the conservative approach for our main analysis focused on a cohort of persons with relapsing-onset multiple sclerosis who were naïve to disease-modifying therapy when the beta interferons were first approved, our complementary analyses, with study entry 10 years earlier and imputation of Expanded Disability Status Scale scores to include those with missing disability assessments, enabled inclusion of more cases; both provided similar findings of a survival advantage with beta interferon treatment. Because treatment status was unknown for some persons with relapsing-onset multiple sclerosis in the French cohort, they were censored at their last clinic visit. However, imputation of exposure to beta interferon treatment and re-analysis after inclusion of their additional available follow-up time did not change the

interpretation of findings. Although the confidence intervals overlapped, the effect size was larger which suggests that any bias due to this missing data would likely have been towards an underestimate of the association.

As with all observational studies, there is potential for residual confounding, despite our consideration of important predictors of mortality through matching or adjustment; information on smoking, or other health behaviours, for example were not captured. Indication bias cannot be completely ruled out; it is feasible that non-responders to treatment, or those with declining health, might have stopped treatment early and the results of the cumulative exposure analyses should therefore be interpreted cautiously. On the other hand, a survival advantage was observed even in the complementary analysis with exposure to disease-modifying therapy determined as any treatment at all (at least one day), akin to an ‘intention to treat’ approach. This ensured that responders and non-responders, and those who stopped treatment very early, were all considered treated. It has been suggested that an indication bias with beta interferon might be driven by a greater likelihood of treatment among persons with multiple sclerosis who are progressing or not doing well (Sormani and Bruzzi, 2015). If this were true it would tend to bias observed differences towards the null, implying that our estimates could be conservative. It is important to note that due to lower exposure rates to glatiramer acetate and the other multiple sclerosis therapies during the follow-up period there was insufficient power to assess their association with, or potential impact on, survival. These exposures were considered only as potential confounders of the relationship between beta interferon and survival and measures of their effect on survival cannot be interpreted from these analyses.

Our study provides evidence for a significant survival advantage among people with relapsing-onset multiple sclerosis who are exposed to beta interferons during routine clinical practice.

Further, a dose-response effect was observed with an increased survival associated with longer cumulative exposure to beta interferon.

Worldwide, the beta interferons remain the most commonly used disease-modifying therapies to treat multiple sclerosis. These findings provide additional valuable information for patients and clinicians with respect to important and realistic treatment outcomes. Further work is warranted to assess whether this survival advantage extends to other disease-modifying therapies for multiple sclerosis and whether this observed survival advantage results in a measurable improvement in the quality of life lived.

ACKNOWLEDGEMENTS

We thank *Répertoire National d'Identification des Personnes* and *Institut National de la Santé et de la Recherche Médicale* for approval and support with accessing French national mortality data; the BC Ministry of Health, and the BC Vital Statistics Agency for approval and support with accessing BC provincial data; and Population Data BC for facilitating approval and use of the data. All inferences, opinions, and conclusions drawn in this publication are those of the authors, and do not reflect the opinions or policies of the Data Steward(s).

We gratefully acknowledge the BC and Rennes multiple sclerosis clinic patients and neurologists who contributed and facilitated access to clinical data. We are also grateful to the research assistants who contributed to the data collection/cleaning in Rennes (Perdomo Liliana) and BC (Tom Duggan). Data collection in Rennes, France, has been supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "Investments for the Future" programme, under the reference ANR-10-COHO-002.

Ethics approval was provided by the Clinical Research Ethics Board of the University of British Columbia (# H06-70455), the French Advisory Committee for Data Processing in Health Research (*Comité Consultatif du Traitement de l'Information en matière de Recherche dans le domaine de la Santé*; #14.489) and the National Data Protection and Privacy Commission (*Commission Nationale Informatique et Libertés*; # DR-2014-571).

FUNDING

The study was supported by research grants from the National Multiple Sclerosis Society (RG#:5064-A-5) to Dr Tremlett, and La Fondation pour l'aide à la recherche sur la sclérose en plaques (Fondation ARSEP) to Drs Leray, Kingwell and Tremlett. Dr Joel Oger received support from the Christopher Foundation and the University of British Columbia.

The funding agencies had no role in the design and conduct of this study; collection, management, analysis or interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

COMPETING INTERESTS

Dr Kingwell, Mr Zhu and Prof. Oger have no competing interests to report. *Dr Leray* reports grants from the French National Security Agency of Medicines and Health Products, the EDMUS Foundation and Roche SAS; and personal fees from Novartis, MedDay Pharmaceuticals and Roche SAS, all outside of the submitted work. *Prof. Petkau* holds research funding from the Natural Sciences and Engineering Research Council of Canada, and has received consulting fees or fees for service on Data Safety Monitoring Boards from Biogen, the Canadian Study Group on CCSVI, Novartis, and Teva Pharmaceuticals Europe, all outside of the submitted work. *Prof. Edan* has received personal fees from Sanofi, and personal fees and grants from Bayer, Merck Serono, Teva Pharma, Biogenidec, and Novartis, all outside of the submitted work. *Prof. Tremlett* is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis and receives research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation. In addition, in the last five years, *Prof Tremlett* has received research support from the Multiple Sclerosis Society of Canada (Don Paty Career Development Award); the Michael Smith Foundation for Health Research (Scholar Award) and the UK MS Trust; speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres (2013), the National MS Society (2014, 2016),ECTRIMS (2013, 2014, 2015, 2016, 2017, 2018), Biogen Idec (2014), American Academy of Neurology (2013, 2014, 2015, 2016). All speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by Prof. Tremlett's research group.

REFERENCES

- Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. *Neurology* 2011; 76(1 Suppl 1): S14-25.
- Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. *Brain* 2004; 127(Pt 4): 844-50.
- Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. *N Engl J Med* 2000; 343(20): 1430-8.
- de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, *et al.* Evaluating the safety of beta-interferons in MS: A series of nested case-control studies. *Neurology* 2017; 88(24): 2310-20.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992; 45(6): 613-9.
- Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. *Neurology* 2010; 74 Suppl 1: S17-24.
- Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. *BMC Med Res Methodol* 2005; 5(1): 5.
- European Study Group on Interferon B-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. *Lancet* 1998; 352(9139): 1491-7.
- Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, *et al.* Association between beta-interferon exposure and hospital events in multiple sclerosis. *Pharmacoepidemiol Drug Saf* 2014; 23(11): 1213-22.
- Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. *Neurology* 2011; 76(1 Suppl 1): S26-34.
- Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. *J Gen Virol* 2000; 81(Pt 10): 2341-64.

Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, *et al.* Causes of death among commercially insured multiple sclerosis patients in the United States. *PLoS One* 2014; 9(8): e105207.

Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, *et al.* Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study. *BMJ Open* 2012a; 2(6).

Goodin DS, Reder AT. Evidence-based medicine: promise and pitfalls. *Mult Scler* 2012; 18(7): 947-8.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, *et al.* Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. *Neurology* 2012b; 78: 1315-22.

Gronseth GS, Ashman E. The AAN response to evidence-based medicine: promise and pitfalls. *Mult Scler* 2012; 18(7): 949-50.

Grytten Torkildsen N, Lie S, Aarseth J, Nyland H, Myhr K. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. *Mult Scler* 2008; 14(9): 1191-8.

IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. *Neurology* 1993; 43(4): 655-61.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, *et al.* Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol* 1996; 39(3): 285-94.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, *et al.* Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology* 1995; 45(7): 1268-76.

Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, *et al.* A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. *Eur J Neurol* 2006; 13(1): 61-71.

Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, *et al.* Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. *J Neurol Neurosurg Psychiatry* 2012; 83(1): 61-6.

Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. *J Neurol Neurosurg Psychiatry* 1998; 65(1): 56-9.

Leray E, Morrissey SP, Yaouanq J, Coustans M, Le Page E, Chaperon J, *et al.* Long-term survival of patients with multiple sclerosis in West France. *Mult Scler* 2007; 13(7): 865-74.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Seze J, *et al.* Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. *PLoS One* 2015; 10(7): e0132033.

Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. *J Neurol Neurosurg Psychiatry* 2017; 88(8): 621-5.

Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Leung S, *et al.* Effect of comorbidity on mortality in multiple sclerosis. *Neurology* 2015; 85(3): 240-7.

Midgard R, Albrektsen G, Riise T, Kvale G, Nyland H. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway. *J Neurol Neurosurg Psychiatry* 1995; 58(4): 417-21.

Multiple Sclerosis International Federation. Atlas of MS [2013]. London, UK.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. *Lancet* 1998; 352(9139): 1498-504.

Rodriguez-Antiguedad Zarranz A, Mendibe Bilbao M, Llarena Gonzalez C, Audicana C. Mortality and Cause of Death in Multiple Sclerosis: Findings from a Prospective Population-Based Cohort in Bizkaia, Basque Country, Spain. *Neuroepidemiology* 2014; 42(4): 219-25.

Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. *Neurology* 1991; 41(8): 1193-6.

Salter A, Tyry T, Wang G, Fox RJ, Cutter G, Marrie RA. Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. *Neurol Clin Pract* 2016; 6(5): 397-408.

Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. *Neurology* 2013; 81(2): 184-92.

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. *Neurology* 2001; 56(11): 1496-504.

Signori A, Gallo F, Bovis F, Di Tullio N, Maietta I, Sormani MP. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. *Mult Scler Relat Disord* 2016; 6: 57-63.

Smestad C, Sandvik L, Celius EG. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. *Mult Scler* 2009; 15(11): 1263-70.

Sormani MP, Bruzzi P. Can we measure long-term treatment effects in multiple sclerosis? *Nat Rev Neurol* 2015; 11(3): 176-82.

Suissa S. Immortal time bias in pharmaco-epidemiology. *Am J Epidemiol* 2008; 167(4): 492-9.

Sumelahti ML, Hakama M, Elovaara I, Pukkala E. Causes of death among patients with multiple sclerosis. *Mult Scler* 2010; 16(12): 1437-42.

The OWIMS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. *Neurology* 1999; 53(4): 679-86.

Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2015(9): CD011381.

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. *Neurology* 2009; 73(20): 1616-23.

Tsai CP, Lee CT. Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008. *Clin Drug Investig* 2013; 33(9): 647-52.


Westad A, Venugopal A, Snyder E. The multiple sclerosis market. *Nat Rev Drug Discov* 2017; 16(10): 675-6.

FIGURE LEGEND

Figure 1: Algorithm to classify multiple sclerosis-related death based on the underlying cause and multiple sclerosis as a contributing cause from the death certificate among people with multiple sclerosis

All deaths with multiple sclerosis listed as the underlying cause were considered to be multiple sclerosis-related, as were deaths attributed (as the underlying cause) to suicide, certain diseases of the nervous system, sepsis, respiratory infection/inflammation or genitourinary system infection. Deaths due to certain other underlying causes; diseases of the circulatory system, malnutrition, dementia, other specific nervous system diseases, accidents and complications of medical care, were considered multiple sclerosis-related *only* if multiple sclerosis was mentioned as contributing to the death. Lastly, the remaining underlying causes, including cancer, were considered as not multiple sclerosis-related whether multiple sclerosis was mentioned as contributing or not.

The cause of death data from the death certificate were accessed through the British Columbia Vital Statistics Agency in Canada and the ‘Répertoire National d’Identification des Personnes,’ and ‘Institut National de la Santé et de la Recherche Médicale’ in France. The underlying and contributing causes were coded by International Classification of Diseases version 9 and 10 codes. The International Classification of Diseases-10 chapters were used to guide formulation and visualization of the algorithm.



**Table 1: Characteristics of the all-cause death cases and their matched controls
from the combined Canadian and French Multiple Sclerosis cohorts**

	^a CASES (n=649)	^b CONTROLS (n=8,412)	^c P value	
^d Age in years; mean (SD)	50.7 (11.4)	50.3 (10.6)	0.002	
Sex; n (%)	Men	195 (30.0)	195 (30.0)	
	Women	454 (70.0)	454 (70.0)	n/a
Country; n (%)	Canada (British Columbia)	569 (87.7)	569 (87.7)	
	France (Rennes)	80 (12.3)	80 (12.3)	n/a
Expanded Disability Status Scale; n (%)	≤ 3.0	160 (24.7)	160 (24.7)	
	3.5 - 5.0	131 (20.2)	131 (20.2)	
	5.5 - 6.5	164 (25.3)	164 (25.3)	n/a
	7 - 9.5	194 (29.9)	194 (29.9)	
^e Socioeconomic status; n (%)	Lowest	108 (19.0)	99.2 (17.4)	
	Mid-Low	93 (16.3)	94.1 (16.5)	
	Middle	105 (18.5)	114.7 (20.2)	
	Mid-High	132 (23.2)	126.9 (22.3)	
	Highest	107 (18.8)	117.7 (20.7)	0.20
^d Disease duration (years); mean (SD)	17.1 (11.4)	17.5 (7.9)	0.42	
^f Comorbidity Index; mean (SD)	0.24 (0.65)	0.18 (0.25)	0.02	

^g Follow-up time (years); mean (SD)	9.3 (4.6)	9.3 (4.6)	n/a
^h Disease modifying therapies; n (%)			
Beta interferon	85 (13.1)	113.3 (17.4)	0.004
Glatiramer acetate	24 (3.7)	24.1 (3.7)	0.77
Other disease-modifying therapies ⁱ	45 (6.9)	42.0 (6.5)	0.36
<i>Cumulative dose beta interferon; n (%)</i>			
Lower (six months - three years)	53 (8.2)	49.4 (7.6)	
Higher (more than three years)	32 (4.9)	63.8 (9.8)	<0.001
<i>Early / Late Start beta interferon; n (%)</i>			
Time since onset			
Early (less than five years)	31 (4.8)	29.9 (4.6)	
Late (at least five years)	54 (8.3)	83.4 (12.8)	0.003
Age			
Early (under 40 years)	24 (3.7)	28.0 (4.3)	
Late (40 years or over)	61 (9.4)	85.3 (13.1)	0.01

^a649 of 742 deaths were successfully matched to at least one control. After matching 100% of the deaths by sex, six cases did not have a match for age or Expanded Disability Status Scale. For the remaining 87 unmatched cases, there was no available control with a matching calendar year. ^bTo account for variation in the number of controls per case (1-20) between risk sets, all means, SDs, n and % presented here were weighted by the inverse of the number of controls in each set. ^cUnivariate conditional logistic regression ^dMeasured at study entry. ^eSocioeconomic status (neighbourhood income quintile measured at study entry (for the 569 Canadian cases and their controls only); 4% of the cases and 3% of their controls had an unknown SES (missing) at study entry ^fCharlson Comorbidity Index measured during the 12 months before study entry (for the 569 Canadian cases and their controls only); potential scores range from zero to 9.0 and a higher score indicates greater comorbidity burden ^gFollow-up time from study entry date to death in the cases and equivalent time point for the controls. ^hDisease-modifying therapy exposure during follow-up; beta interferon and glatiramer acetate exposure defined as at least six months; Other disease-modifying therapy exposure defined as any exposure. Key: SD: Standard deviation. n/a: not applicable (as cases and controls were matched as per the study design).

Table 2: Estimates of association between beta interferon exposure and all-cause death for the Canadian and French multiple sclerosis cohorts separately and combined.

^a OR (95% CI)	CANADA	FRANCE	COMBINED
	^f Cases: 569	^f Cases: 80	^f Cases: 649
^b Beta interferon	0.67 (0.50 - 0.90)	0.67 (0.35 - 1.28)	0.68 (0.53 - 0.89)
^b Glatiramer acetate	1.26 (0.73 - 2.16)	0.78 (0.32 - 1.92)	1.11 (0.70 - 1.78)
^c Other disease-modifying therapy	1.26 (0.69 - 2.28)	1.37 (0.76 - 2.46)	1.27 (0.84 - 1.92)
^d Age in years	1.04 (1.01 - 1.07)	1.04 (0.95 - 1.15)	1.04 (1.01 - 1.07)
^e Comorbidity burden	1.18 (1.02 - 1.36)		
^b <i>Cumulative days of beta interferon</i>			
Lower (six months to three years)	0.95 (0.67 - 1.36)	1.11 (0.52 - 2.40)	1.00 (0.73 - 1.38)
Higher (more than three years)	0.46 (0.30 - 0.70)	0.37 (0.15 - 0.95)	0.44 (0.30 - 0.66)
^b <i>Early / Late Start beta interferon</i>			
Time since onset			
Early (less than five years)	1.16 (0.73 - 1.85)	0.34 (0.10 - 1.19)	0.93 (0.61 - 1.43)
Late (five or more years)	0.54 (0.38 - 0.76)	0.84 (0.42 - 1.69)	0.61 (0.45 - 0.83)
Age			
Early (under 40 years)	0.89 (0.49 - 1.59)	0.58 (0.19 - 1.77)	0.83 (0.49 - 1.40)
Late (40 years or older)	0.63 (0.46 - 0.87)	0.72 (0.34 - 1.53)	0.65 (0.48 - 0.87)

^aAll ORs are adjusted. Model covariates: beta interferon exposure, glatiramer acetate exposure, other disease-modifying therapy exposure, age at study entry and, for Canada only, comorbidity burden calculated for the year before study entry. ^bReference category is less than six months exposure. ^cReference category is no exposure. ^dAge in years (continuous). ^eCharlson Comorbidity Index. ^fThere were between 1 and 20 matched controls for each case. Key: OR = Odds ratio; CI = Confidence interval; bold indicates p<0.05.

Table 3: Estimates of association between beta interferon exposure and all-cause deaths for the combined Canadian and French multiple sclerosis cohorts by sex

^a OR (95% CI)	WOMEN ^c Cases: 454	MEN ^c Cases: 195
^b Beta interferon	0.78 (0.58 - 1.06)	0.42 (0.24 - 0.77)
^b Glatiramer acetate	1.19 (0.71 - 2.02)	0.89 (0.31 - 2.53)
^c Other disease-modifying therapy	1.68 (1.06 - 2.67)	0.54 (0.21 - 1.42)
^d Age	1.05 (1.01 - 1.08)	1.03 (0.98 - 1.09)
^b <i>Cumulative exposure beta interferon</i>		
Lower (six months to three years)	1.25 (0.86 - 1.81)	0.55 (0.28 - 1.08)
Higher (more than three years)	0.49 (0.32 - 0.76)	0.29 (0.12 - 0.70)
^b <i>Early / Late Start beta interferon</i>		
Time since onset		
Early (less than five years)	1.08 (0.68 - 1.73)	0.47 (0.16 - 1.36)
Late (five or more years)	0.68 (0.47 - 0.97)	0.42 (0.22 - 0.78)
Age		
Early (under 40 years)	0.99 (0.55 - 1.80)	0.49 (0.16 - 1.44)
Late (40 years or older)	0.74 (0.53 - 1.03)	0.41 (0.20 - 0.80)

^aModel covariates: beta interferon exposure, glatiramer acetate exposure, other disease-modifying therapy exposure, age at study entry in years. ^bReference category = Less than six months exposure. ^cReference category = No exposure. ^dAge in years (continuous). ^eThere were between 1 and 20 matched controls for each case. OR = Odds ratio; CI = Confidence interval; bold indicates statistically significant estimates (p<0.05).

**Multiple sclerosis:
Effect of beta-interferon treatment on survival**

Elaine Kingwell, PhD, Emmanuelle Leray, PhD, Feng Zhu, MSc,

John Petkau, PhD, Gilles Edan, MD, Joel Oger, MD, Helen Tremlett, PhD.

SUPPLEMENTARY MATERIAL

Abbreviations:

CI Confidence interval; OR Odds ratio; SD Standard deviation

Table of Contents

Supplementary Methods 1: Description and sources of the clinical and administrative health data	2
Supplementary Methods 2: Complementary analyses methods and results.....	3
1. Earlier Study Entry Date (1986)	3
2. Imputation of missing Expanded Disability Status Scale scores	4
3. ‘Intention to Treat’	4
4. Imputation of unknown beta interferon exposure status in the French cohort.....	5
Supplementary Tables.....	6
Supplementary Table 1: Data sources and years of availability in British Columbia, Canada and Rennes, France.....	6
Supplementary Table 2: Number of controls per case for the 649 cases included in the main analysis of beta-interferon treatment for multiple sclerosis and mortality.....	7
Supplementary Table 3: Estimates of association between all-cause deaths and disease modifying drug exposure for the Canadian and French multiple sclerosis cohorts separately and combined with earliest study entry date of 1 st January 1986.....	8
Supplementary Table 4: Estimates of association between all-cause deaths and disease modifying drug exposure for the Canadian and French multiple sclerosis cohorts separately and combined with imputed Expanded Disability Status Scale scores.....	9
Supplementary Table 5: Estimates of association between all-cause deaths and disease modifying drug exposure for the Canadian and French multiple sclerosis cohorts separately and combined using the ‘Intention to Treat’ approach	10
Supplementary Table 6: Estimate of association between all-cause deaths and disease modifying drug exposure for the French multiple sclerosis cohort with imputation of unknown beta interferon exposure..	11

Supplementary Methods 1: Description and sources of the clinical and administrative health data

The cohort included all adults with relapsing-onset multiple sclerosis initially registered at one of the four multiple sclerosis clinics in British Columbia (1980-2004) or the Rennes multiple sclerosis clinic (1976-2013), and diagnosed by a multiple sclerosis-specialist neurologist by Poser or McDonald criteria (Poser *et al.*, 1983; McDonald *et al.*, 2001). The multiple sclerosis clinical databases in British Columbia and Rennes (Leray *et al.*, 2007; Tremlett *et al.*, 2010), provided the following information: sex, birthdate, symptom onset date, disease course, Expanded Disability Status Scale scores, and initiation/cessation dates of the disease-modifying therapies for multiple sclerosis including immunosuppressants. Dates and causes of death were accessed from the British Columbia Vital Statistics Agency (BC Vital Statistics Agency, 2015), the French ‘Répertoire National d’Identification des Personnes,’ and the ‘Institut National de la Santé et de la Recherche Médicale’. British Columbia drug prescription data was provided by PharmaNet (British Columbia Ministry of Health, 2015a); this data extract captured all dispensations of disease modifying drugs at community and outpatient pharmacies in British Columbia and complemented the drug exposure data from the British Columbia Multiple Sclerosis database. The Medical Service Plan (British Columbia Ministry of Health, 2015b) provided dates and International Classification of Diseases System diagnostic codes for physician visits, and the Discharge Abstracts (British Columbia Ministry of Health, 2015c) data provided dates and diagnostic codes for all hospital admissions. Registration dates in the provincial health care plan and quintiles of neighbourhood level socioeconomic status were accessed from the British Columbia Registration and Premium Billing files (British Columbia Ministry of Health, 2015d). The time periods of data availability and sources of the administrative data are shown in Supplementary Table 1.

Supplementary Methods 2: Complementary analyses methods and results

Complementary analyses were conducted to facilitate inclusion of additional data, follow-up time or patients, and to test assumptions:

1. Allowing an earlier study entry (1st January 1986)
2. Imputing Expanded Disability Status Scale scores for those without a score at study entry
3. ‘Exposure’ to beta interferon or glatiramer acetate classified as any exposure of at least one day (akin to an ‘Intention to Treat’ approach).
4. Imputation of unknown beta interferon exposure status for the French cohort

Details of these methods and the results of these analyses are outlined below.

1. Earlier Study Entry Date (1986)

Methods

To include the potential multiple sclerosis cases and controls with disease-modifying therapy or immunosuppressant exposure prior to 1996, the earliest study entry date was set at 1st January 1986. All methods used to select cases and controls remained the same. Also, the same analytical approach was used as for the main analysis, but without adjustment for comorbidity in British Columbia, Canada because some of the required information, i.e. diagnostic codes generated from physician encounters, was not available pre-1991. This complementary approach enabled: (i) inclusion of those patients who were exposed to disease-modifying therapies, including beta interferon or immunosuppressants, before approval of beta interferon in Canada and France and who were therefore excluded from the main analyses; and (ii) a longer potential follow-up time (up to 28 years; from 1986 to 2013). Individuals with no available Expanded Disability Status Scale score within three years of their study entry date were excluded.

Results

There were 1,096 deaths in the multiple sclerosis cohort between 1986 and the end of 2013 and the mean age at death was 61 (SD 13) years. Of these, 892 were successfully matched to up to 20 controls. In comparison to the main analysis, the earlier study entry date allowed inclusion of a larger number of cases from the Canadian cohort (820) and slightly less from the French cohort (72), due to missing Expanded Disability Status Scale scores in the earlier years. The cases and controls were younger than those in the main analysis (mean age 41 years; SD 9) and had a shorter multiple sclerosis disease duration (mean of 10 years; SD 9) at study entry, as expected due to the potentially earlier study entry date. After adjustment for age and exposure to glatiramer acetate or other disease-modifying therapies,

persons who were exposed to beta interferon had a higher odds of survival compared to persons who were not exposed (OR:0.62; 95% CI 0.49-0.80); i.e. findings were consistent with those from the main analysis. The results are shown in Supplementary Table 3.

2. Imputation of missing Expanded Disability Status Scale scores

Methods

The main analysis (with 1st January 1996 as the study entry) was repeated with inclusion of all individuals regardless of whether their Expanded Disability Status Scale score was available; for individuals without a score at study entry, the score was imputed 10 times based on age, sex, multiple sclerosis disease duration and country with the proportional odds model.

The methods used for the main analyses were repeated but with matching of controls to cases by sex, age (+/- five years), calendar year and country, and not by category of Expanded Disability Status Scale. The conditional logistic regression models were adjusted for EDSS (as a continuous measure), age, glatiramer acetate exposure and other disease-modifying therapy exposure, and for comorbidity in Canada.

Results

After inclusion of individuals with missing Expanded Disability Status Scale score at study entry, the combined Canadian and French cohort included 7,009 persons with relapsing-onset multiple sclerosis who were naïve to disease-modifying therapy at study entry; 75% were women and the mean age was 42 (SD 12) years. There were 989 all cause deaths and 956 of these cases were successfully matched to up to 20 controls by sex, age and calendar year at entry. The cases and controls had an average age of 50 years (SD 9) at entry (similar to the average age of the cases and controls included in the main analysis). After adjustment for Expanded Disability Status Scale score, age and exposure to glatiramer acetate or other disease-modifying therapies, similar estimates to the main analysis were obtained.

Persons with relapsing-onset multiple sclerosis who were exposed to beta interferon had a higher odds of survival compared to those who were not exposed; the results from the 10 imputations were very similar (OR:0.62; 95% CI 0.49-0.78). The full model results are shown in Supplementary Table 4.

3. ‘Intention to Treat’

Methods

The main analysis (with 1st January 1996 as the study entry) was repeated with exposure to beta interferon, and to glatiramer acetate, defined as at least one day. This ‘Intention to Treat’ analysis

ensured that responders and non-responders, and those that stopped treatment very early, were all considered treated.

Results

The same 649 cases and their matched controls from the main analysis were included. Persons with relapsing-onset multiple sclerosis who were exposed to beta interferon had a higher odds of survival compared to those who were not exposed (OR:0.76; 95% CI:0.59-0.97); estimates were similar to those derived from the main analysis. The results are shown in Supplementary Table 5.

4. Imputation of unknown beta interferon exposure status in the French cohort

Methods

The main analysis (with 1st January 1996 as the study entry) was repeated for the French cohort. For those with unknown beta interferon treatment status after their last clinic visit (i.e. less than 180 days exposure to this date), the number of days of beta interferon exposure were imputed over the period between the last multiple sclerosis clinic visit and study end, based on age, sex, Expanded Disability Status Scale score and disease duration with the Markov Chain Monte Carlo method; this was repeated 10 times. As death/survival information was available for all persons with multiple sclerosis, this allowed inclusion of all follow-up time for the French cohort. As for the main analyses, controls were matched to cases by sex, age (+/- five years), calendar year and Expanded Disability Status Scale score. The conditional logistic regression model was adjusted for age only; with a second model adjusted for age, glatiramer acetate and other disease-modifying therapy exposure (exposure status to glatiramer acetate and other disease-modifying therapies were based on the status recorded at the last clinic visit, with no change assumed through to the study end).

Results

The treatment status after the last clinic visit was unknown for 528 patients in the French cohort. With imputation of treatment status and inclusion of the follow-up time after the last clinic visit for these individuals, 95 all cause deaths were successfully matched with up to 20 controls. After adjustment for age, and then for age, glatiramer acetate or other disease-modifying therapy exposure, the estimates of the effect of beta interferon were comparable, or even greater, than those seen in the main analysis (although all CIs overlapped). Persons with multiple sclerosis who were exposed to beta interferon had a lower risk of death compared to those who were not exposed; the results from the 10 repeated imputations were very similar (OR:0.23; 95% CI 0.13-0.41). The full model results are shown in Supplementary Table 6.

Supplementary Tables

Supplementary Table 1: Data sources and years of availability in British Columbia, Canada and Rennes, France

	British Columbia, Canada	Rennes, France
<u>Description of source cohorts</u>		
	<i>Adults (≥ 18 years), relapsing-onset multiple sclerosis, registered at a British Columbia multiple sclerosis clinic 1980 - 2004</i>	<i>Adults (≥ 18 years), relapsing-onset multiple sclerosis, registered at the Rennes multiple sclerosis clinic 1976 - 2013</i>
<u>Data elements</u>		
<u>Databases accessed and dates of data availability</u>		
Sex; birth date; onset date; disease course; Expanded Disability Status Scale scores; beta interferon, glatiramer acetate and all other disease-modifying therapy start/stop dates	British Columbia Multiple Sclerosis Database 1980 - 2008	Rennes Multiple Sclerosis Database 1976 - 2013
Death date; all causes listed on the death certificate	British Columbia Vital Statistics Deaths 1986 – 2013	Répertoire National d'Identification des Personnes,' and the 'Institut National de la Santé et de la Recherche Médicale' January 1986 - 2013
Prescriptions filled (dispensed), including disease-modifying therapies	British Columbia PharmaNet 1996 – 2013	N/A
Physician visit dates; International Classification of Diseases codes	British Columbia Medical Services Plan, 1991 – 2013	N/A
Hospital admission and discharge dates; International Classification of Diseases codes	British Columbia Discharge Abstract Database 1986 – 2013	N/A
Registration/ cancellation dates in the British Columbia health care program; socioeconomic status	British Columbia Registration and Premium Billing files, 1986 – 2013	N/A

N/A = not applicable

Supplementary Table 2: Number of controls per case for the 649 cases included in the main analysis of beta-interferon treatment for multiple sclerosis and mortality

Number of controls per case	Number of cases (of 649 in total)
1	54
2	43
3	28
4	24
5	31
6	16
7	11
8	17
9	19
10	16
11	15
12	12
13	12
14	8
15	7
16	13
17	10
18	8
19	7
20	298

Supplementary Table 3: Estimates of association between all-cause deaths and disease modifying drug exposure for the Canadian and French multiple sclerosis cohorts separately and combined with earliest study entry date of 1st January 1986

^a OR (95% CI)	CANADA	FRANCE	COMBINED
	^c Cases: 820	^c Cases: 72	^c Cases: 892
^b Beta interferon	0.60 (0.46 - 0.78)	0.87 (0.42 - 1.79)	0.62 (0.49 - 0.80)
^b Glatiramer acetate	1.17 (0.70 - 1.95)	0.71 (0.25 - 2.03)	1.06 (0.67 - 1.69)
^c Other disease-modifying therapy	1.50 (0.96 - 2.36)	1.71 (0.87 - 3.38)	1.52 (1.05 - 2.20)
^d Age	1.04 (1.02 - 1.07)	1.08 (0.97 - 1.21)	1.05 (1.02 - 1.07)
^b <i>Cumulative exposure beta interferon</i>			
Lower (six months to three years)	0.80 (0.58 - 1.12)	1.81 (0.76 - 4.27)	0.90 (0.66 - 1.22)
Higher (more than three years)	0.43 (0.29 - 0.63)	0.33 (0.10 - 1.02)	0.41 (0.29 - 0.59)
^b <i>Early / Late Start beta interferon</i>			
Time since onset			
Early (less than five years)	1.09 (0.68 - 1.76)	0.42 (0.11 - 1.52)	0.91 (0.58 - 1.42)
Late (at least 5 years)	0.50 (0.37 - 0.68)	1.18 (0.53 - 2.64)	0.56 (0.42 - 0.74)
Age			
Early (under 40 years)	0.88 (0.49 - 1.58)	0.60 (0.20 - 1.79)	0.79 (0.48 - 1.33)
Late (40 years or older)	0.55 (0.41 - 0.74)	1.13 (0.46 - 2.78)	0.59 (0.45 - 0.77)

^aModel covariates: beta interferon exposure, glatiramer acetate exposure, other disease-modifying therapy exposure and age at study entry. ^bReference category = Less than six months exposure. ^cReference category = No exposure. ^dAge in years (continuous). ^eThere were between one and 20 matched controls for each case. OR = Odds ratio; CI = Confidence interval; bold indicates statistically significant estimates (p<0.05).

Supplementary Table 4: Estimates of association between all-cause deaths and disease modifying drug exposure for the Canadian and French multiple sclerosis cohorts separately and combined with imputed Expanded Disability Status Scale scores

^a OR (95% CI)	CANADA ^g Cases: 834	FRANCE ^g Cases: 122	COMBINED ^g Cases: 956
^b Beta interferon	0.63 (0.49 – 0.81)	0.61 (0.36 – 1.05)	0.62 (0.49 - 0.78)
^b Glatiramer acetate	1.22 (0.76 – 1.96)	1.22 (0.61 – 2.41)	1.22 (0.81 - 1.59)
^c Other disease-modifying therapy	1.02 (0.58 – 1.79)	1.15 (0.73 – 1.79)	1.14 (0.83 – 1.79)
^d Expanded Disability Status Scale	1.30 (1.26 – 1.34)	1.49 (1.35 – 1.65)	1.32 (1.28 – 1.36)
^e Age	1.06 (1.03 – 1.08)	1.03 (0.96 – 1.11)	1.06 (1.03 – 1.08)
^f Comorbidity burden	1.20 (1.08 – 1.34)		
^b <i>Cumulative exposure beta interferon</i>			
Lower (six months to three years)	0.86 (0.63 – 1.18)	1.04 (0.55 – 1.97)	0.89 (0.67 – 1.17)
Higher (more than three years)	0.44 (0.30 – 0.65)	0.30 (0.13 – 0.73)	0.40 (0.28 – 0.57)
^b <i>Early / Late Start beta interferon</i>			
Time since onset			
Early (less than five years)	1.21 (0.81 – 1.81)	0.28 (0.09 – 0.84)	0.87 (0.60 – 1.28)
Late (at least 5 years)	0.49 (0.36 – 0.67)	0.78 (0.44 – 1.38)	0.54 (0.41 – 0.71)
Age			
Early (under 40 years)	0.86 (0.52 – 1.44)	0.45 (0.19 – 1.09)	0.72 (0.46 – 1.11)
Late (40 years or older)	0.58 (0.43 – 0.77)	0.72 (0.39 – 1.35)	0.59 (0.46 – 0.77)

^aModel covariates: beta interferon exposure, glatiramer acetate exposure, other disease-modifying therapy exposure, EDSS at study entry, age at study entry and, for Canada only, comorbidity burden calculated for the year before study entry. ^bReference category = Less than six months exposure. ^cReference category = No exposure. ^dExpanded Disability Status Scale as a continuous measure. ^eAge in years (continuous). ^fCharlson Comorbidity Index ^gThere were between one and 20 matched controls for each case.
OR = Odds ratio; CI = Confidence interval. Bold indicates statistically significant estimates (p<0.05).

Supplementary Table 5: Estimates of association between all-cause deaths and disease modifying drug exposure for the Canadian and French multiple sclerosis cohorts separately and combined using the ‘Intention to Treat’ approach

^a OR (95% CI)	CANADA	FRANCE	COMBINED
	^e Cases: 569	^e Cases: 80	^e Cases: 649
^b Beta interferon	0.73 (0.55-0.96)	0.81 (0.43-1.53)	0.76 (0.59-0.97)
^b Glatiramer acetate	1.46 (0.92-2.33)	0.75 (0.32-1.75)	1.24 (0.82-1.88)
^b Other disease-modifying therapy	1.24 (0.68-2.26)	1.39 (0.77-2.50)	1.26 (0.84-1.90)
^c Age	1.04 (1.01-1.08)	1.04 (0.95-1.15)	1.04 (1.01-1.07)
^d Comorbidity burden	1.17 (1.02-1.35)		

^aModel covariates: IFNB exposure (at least one day), glatiramer acetate exposure (at least one day), other disease-modifying therapy exposure (at least one day), age at study entry in years and for Canada only, comorbidity burden calculated for the year before study entry. ^bReference category = No disease-modifying therapy exposure. ^cAge in years (continuous). ^dCharlson Comorbidity Index. ^eThere were between one and 20 matched controls for each case.

OR = Odds ratio; CI = Confidence interval. Bold indicates statistically significant estimates (p<0.05).

Supplementary Table 6: Estimate of association between all-cause deaths and disease modifying drug exposure for the French multiple sclerosis cohort with imputation of unknown beta interferon exposure

^a OR (95%CI)	⁵ Cases: 95
^c Beta interferon	0.23 (0.13-0.41)
^d Age	1.07 (0.98-1.59)
^b OR (95%CI)	
^c Beta interferon	0.23 (0.13-0.41)
^c Glatiramer acetate	0.98 (0.40-2.39)
^c Other disease-modifying therapy	1.41 (0.84-2.39)
^d Age	1.07 (0.98-1.17)

^aModel covariates: beta interferon exposure (at least 180 days) and age at study entry in years. ^bModel covariates: beta interferon exposure (at least 180 days), age at study entry in years, glatiramer acetate exposure at least 180 day), and other disease-modifying therapy exposure (at least one day). ^cReference category = No disease-modifying therapy exposure. ^dAge in years (continuous). ^eThere were between one and 20 matched controls for each case.

OR = Odds ratio; CI = Confidence interval. Bold indicates statistically significant estimates (p<0.05).

References

BC Vital Statistics Agency [creator] (2015). Vital Statistics Deaths. V2. Population Data BC [publisher]. Data Extract BC Vital Statistics Agency. 2015 Available from:

<http://www.popdata.bc.ca/data>

British Columbia Ministry of Health [creator] (2015). PharmaNet. V2. 2015a Available from:

<http://www.popdata.bc.ca/data>

British Columbia Ministry of Health [creator] [2015]. Consolidation File (MSP Registration & Premium Billing). V2. Population Data BC [publisher]. Data Extract MOH. 2015a Available from: <http://www.popdata.bc.ca/data>

British Columbia Ministry of Health [creator] [2015]. Discharge Abstract Database (Hospital Separations). V2. Population Data BC [publisher]. Data Extract MOH. 2015b Available from:

<http://www.popdata.bc.ca/data>

British Columbia Ministry of Health [creator] [2015]. Medical Services Plan (MSP) Payment Information File: Population Data BC [publisher]. Data Extract MOH. 2015c Available from:

<http://www.popdata.bc.ca/data>

Leray E, Morrissey SP, Yaouanq J, Coustans M, Le Page E, Chaperon J, *et al.* Long-term survival of patients with multiple sclerosis in West France. *Mult Scler* 2007; 13(7): 865-74.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, *et al.*

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol* 2001; 50(1): 121-7.

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, *et al.* New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol* 1983; 13(3): 227-31.

Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. *Neurology* 2010; 74(24): 2004-15.